Vesicular Monoamine Transporter 2 Inhibitor [EPC]: Side Effects & Safety Data for 2 Drugs
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
Vesicular Monoamine Transporter 2 Inhibitor [EPC] includes 2 drugs with a combined 28,565 adverse event reports in the FDA FAERS database. Compare their safety profiles, side effects, and outcomes below.
2
Drugs in Class
28,565
Combined Reports
All Vesicular Monoamine Transporter 2 Inhibitor [EPC] Drugs Ranked by Reports
| Drug | Brand Name | Reports | Deaths | Hosp. | Death Rate |
|---|---|---|---|---|---|
| VALBENAZINE | INGREZZA | 23,191 | 1,221 | 3,225 | 5.3% |
| TETRABENAZINE | tetrabenazine | 5,374 | 928 | 990 | 17.3% |
Common Side Effects in Vesicular Monoamine Transporter 2 Inhibitor [EPC] Drugs
| Side Effect | Reports | Deaths |
|---|---|---|
| Drug ineffective | 3,221 | 9 |
| Somnolence | 2,682 | 23 |
| Fatigue | 1,873 | 6 |
| Off label use | 1,707 | 137 |
| Death | 1,644 | 1,639 |
| Tremor | 1,610 | 7 |
| Tardive dyskinesia | 1,457 | 7 |
| Fall | 1,262 | 43 |
| Dizziness | 983 | 5 |
| Dyskinesia | 911 | 10 |